Camp4 Therapeutics Corporation announced a strategic research, collaboration, and license agreement with GSK to identify and develop antisense oligonucleotide $(ASO)$ drug candidates targeting neurodegenerative and kidney diseases. Under the terms of the agreement, Camp4 will receive a $17.5 million upfront payment and is eligible for additional milestone-based payments and tiered royalties on future product sales. Camp4 will utilize its RAP Platform® to identify regulatory RNAs and generate ASO candidates, while GSK will be responsible for further development and commercialization of the candidates identified through the collaboration.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Camp4 Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001736730-25-000111), on December 18, 2025, and is solely responsible for the information contained therein.